Abstract: Objective To investigate the efficacy and safety of albumin bound paclitaxel combined with S-1 as thirdline and beyond therapy for advanced nonsmall cell lung cancer（NSCLC）. Methods Eighteen patients with advanced NSCLC were treated with albumin bound paclitaxel with S-1（Albumin bound paclitaxel was 125 mg／m2 on the first and the eighth day， S-1 was administered at 80mg per day for patients with a body surface area＜125m2， 100mg per day for those with a body surface area of 1.25-1.5m2， and 120mg per day for those with a body surface area≥1.5m2, twice a day， from d1 to d14. Twenty-one days was a cycle）. Each patient received at least 2 cycles. The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.
ResultsAmong 18 NSCLC patients， 4 achieved partial responses， 9 reached stable disease， and 5 reached progressive disease. The response rate（RR） was 22.2％（4/18） and the disease control rate（DCR） was 72.2％（13/18）. The median progressionfree survival time（PFS） was 3.0 months. The common treatment related adverse events were bone marrow suppression， badlness and neurotoxicity, but they were tolerable.
ConclusionDue to its high efficacy， low toxicity and convenient usage， albumin bound paclitaxel combined with S-1 regimen can provide another choice for patients of advanced NSCLC treated with thirdline and beyond therapy.